Recursion Pharmaceuticals
RXRX
334 hedge funds and large institutions have $1.33B invested in Recursion Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 70 funds opening new positions, 123 increasing their positions, 84 reducing their positions, and 52 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 84
36% more call options, than puts
Call options by funds: $40.1M | Put options by funds: $29.5M
35% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 52
4% more funds holding
Funds holding: 322 → 334 (+12)
12.83% less ownership
Funds ownership: 75.87% → 63.04% (-13%)
16% less capital invested
Capital invested by funds: $1.58B → $1.33B (-$256M)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.7M |
| 2 |
BlackRock
New York
|
+$35.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$35M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$18.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIC
Mubadala Investment Company
Abu Dhabi,
United Arab Emirates
|
-$63.4M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$38.7M |
| 3 |
NC
Nvidia Corp
Santa Clara,
California
|
-$37.6M |
| 4 |
Morgan Stanley
New York
|
-$8.09M |
| 5 |
BPCE
Bank Pictet & Cie (Europe)
Frankfurt Am Main,
Germany
|
-$7.95M |
RXRX Hedge Fund Activity: Q4 2025 in Review
334 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2025, worth a combined $1.33B — down 16% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new RXRX positions and 52 closed out — a net gain of 18 holders — while 123 added to existing stakes and 84 trimmed.
The largest buyer was Vanguard Group, adding an estimated $36.7M. The largest seller was Mubadala Investment Company, exiting entirely with an estimated $63.4M sold.
- 334 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2025, up from 322 in Q3 2025.
- Funds reported $1.33B of Recursion Pharmaceuticals stock for Q4 2025, down 16% quarter-over-quarter.
- 70 funds opened new Recursion Pharmaceuticals positions in Q4 2025 and 52 closed out, a net change of +18 holders.
- The largest Recursion Pharmaceuticals buyer in Q4 2025 was Vanguard Group, an estimated $36.7M added.
- The largest Recursion Pharmaceuticals seller in Q4 2025 was Mubadala Investment Company, an estimated $63.4M sold.
Based on aggregated 13F filings for Q4 2025.